Noam Goodman and Gabriella Levkov appointed to Baycrest Health Sciences Research Ethics Board

Noam Goodman and Gabriella Levkov have been appointed to Baycrest Health Sciences’ Research Ethics Board (REB).  The REB is responsible for overseeing ethical approval for all research projects involving Baycrest physicians, staff, students or patients to ensure that all research carried out is reviewed for scientific merit, ethical considerations and resource implications. 

Baycrest provides a continuum of care for older adults, including independent living, assisted living, long-term care and a post-acute hospital specializing in the care of older adults all within one campus. They are a global leader in geriatric residential living, healthcare, research, innovation and education, with a special focus on brain health and aging.

Noam represents a diverse group of Canadian and US Life Sciences companies including pharmaceutical, biotechnology and medical device companies in mergers and acquisitions, private equity, secured finance and the licensing of intellectual property. He has also been at the forefront of legal developments for electronic health records in Canada.

Gabriella practises in the areas of intellectual property and food and drug regulatory law.‎ Her intellectual property practice focuses on patent, trademark and copyright litigation. Gabriella ‎also assists ‎clients with all aspects of regulatory compliance including medical device and natural health ‎product licensing, cosmetic notifications, ‎advertising claims, and packaging and labelling compliance.‎